Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Short-term Investments (2019 - 2023)

Historic Short-term Investments for Marimed (MRMD) over the last 10 years, with Q4 2023 value amounting to $88000.0.

  • Marimed's Short-term Investments fell 2845.53% to $88000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $88000.0, marking a year-over-year decrease of 2845.53%. This contributed to the annual value of $88000.0 for FY2023, which is 2845.53% down from last year.
  • According to the latest figures from Q4 2023, Marimed's Short-term Investments is $88000.0, which was down 2845.53% from $161000.0 recorded in Q3 2023.
  • Marimed's Short-term Investments' 5-year high stood at $1.4 million during Q4 2019, with a 5-year trough of $88000.0 in Q4 2023.
  • Moreover, its 5-year median value for Short-term Investments was $525000.0 (2022), whereas its average is $641833.2.
  • Its Short-term Investments has fluctuated over the past 5 years, first surged by 7215.01% in 2021, then crashed by 9169.99% in 2023.
  • Over the past 5 years, Marimed's Short-term Investments (Quarter) stood at $1.4 million in 2019, then fell by 6.35% to $1.4 million in 2020, then crashed by 81.51% to $251000.0 in 2021, then tumbled by 51.0% to $123000.0 in 2022, then decreased by 28.46% to $88000.0 in 2023.
  • Its Short-term Investments stands at $88000.0 for Q4 2023, versus $161000.0 for Q3 2023 and $102000.0 for Q2 2023.